| Literature DB >> 34935568 |
Xiaopeng Wang1,2, Yiwen Liu3, Yannan Lu4, Simo Chen2, Yaoping Xing2, Haijun Yang1, Xiaojun Wang5, Yaowen Zhang1, Tao Pan6, Junkuo Li1, Min Wang1,2, Ning Zhang3, Mengxia Liang3, Fuyou Zhou1,2,3.
Abstract
BACKGROUND: To analyze the correlation between the inducing effect of Fusobacterium nucleatum (Fn) on the surface expression of the inhibitory receptor KIR2DL1 on CD8+ T cells in oesophageal squamous cell carcinoma (ESCC) and the clinicopathological features and survival prognosis and to explore its clinical significance.Entities:
Keywords: CD8+ T lymphocytes; Fusobacterium nucleatum; KIR2DL1; oesophageal squamous cell carcinomas; prognosis
Mesh:
Substances:
Year: 2022 PMID: 34935568 PMCID: PMC8725851 DOI: 10.1080/07853890.2021.2016942
Source DB: PubMed Journal: Ann Med ISSN: 0785-3890 Impact factor: 4.709
Figure 1.Enrolment criteria and clinicopathological data of 196 ESCC patients.
Figure 2.Fn can induce KIR2DL1 expression on CD8+ T cells. (A) The expression of KIR2DL1 on CD8+ T cells was detected by flow cytometry; (B) The expression of KIR2DL1 on CD8+ T cells among the groups at each time point was compared by one-way ANOVA; (1) Compared with the CD8+ T cells group, p < .05; (2) Compared with the CD8+ T cells + KYSE150 cells group, p < .05; (3) Compared with the CD8+ T cells + Fn group, p < .05.
Figure 3.Fn infection can reduce the sensitivity of tumour cells to CDDP. (A) Apoptosis of KYSE150 cells in the co-culture system was detected by flow cytometry; (B) The apoptosis rate of KYSE150 cells was different among all groups; (C) Differences in tumour size and fluorescence intensity among groups; (D) Differences in tumour weight among groups; (1) Compared to the control group, p < .05; (2) Compared with the Fn group, p < .05; (3) Compared with the CDDP group, p < .05. (E) In vivo imaging was used to measure the tumour size in each mouse group.
Figure 4.Fn infection and KIR2DL1 expression on the surface of CD8+ T cells in ESCC and adjacent tissues (400×). (A,D,G) Representative RNAscope images of Fn infection (16S rRNA); (B,E,H) Representative immunohistochemical images of CD8+ T cell infiltration; (C,F,I) Representative immunohistochemical images of KIR2DL1 expression.
Cohen's kappa coefficients indicate the consistency between Fn infection and expression of the inhibitory receptor KIR2DL1 on the surface of CD8+ T lymphocytes in ESCC [n (%)].
| Fn | Kappa* |
| ||
|---|---|---|---|---|
| Positive | Negative | |||
| CD8+ T cell surface KIR2DL1 | ||||
| Positive | 58 (96.67) | 2 (3.33) | 0.929 | <.001 |
| Negative | 4 (2.94) | 132 (97.06) | ||
*Kappa coefficient >0.7, excellent; 0.4–0.7, good; <0.4, poor agreement.
Comparison of the positive rates of Fn infection in cancer tissues and corresponding adjacent tissues of patients with ESCC [n (%)].
| Group | Cancer |
|
| |
|---|---|---|---|---|
| Fn (+) | Fn (−) | |||
| Paracancerous | ||||
| Fn (+) | 8 (100.00) | 0 (0) | 18.026 | <.001 |
| Fn (−) | 54 (28.72) | 134 (71.28) | ||
Comparison of KIR2DL1 expression on the surface of CD8+ T cells in ESCC tissues and the corresponding paracancerous tissues [n (%)].
| Group | Cancer |
|
| |
|---|---|---|---|---|
| CD8+ + KIR2DL1 (+) | CD8+ + KIR2DL1 (−) | |||
| Paracancerous | ||||
| CD8+ + KIR2DL1 (+) | 6 (100.00) | 0 (0) | 6.88 | <.001 |
| CD8+ + KIR2DL1 (−) | 54 (28.42) | 136 (71.58) | ||
Correlation between positivity for Fn-induced expression of the inhibitory receptor KIR2DL1 on the surface of CD8+ T lymphocytes and clinicopathological features of patients with ESCC [n (%)].
| Clinicopathological feature |
| Fn + CD8+ T + KIR2DL1 |
|
| |
|---|---|---|---|---|---|
| Positive | Negative | ||||
| Sex | |||||
| Male | 128 | 50 (39.06) | 78 (60.94) | 15.883 | <.001 |
| Female | 68 | 8 (11.76) | 60 (88.24) | ||
| Age | |||||
| ≥60 years | 110 | 30 (27.27) | 80 (72.73) | 0.647 | .421 |
| <60 years | 86 | 28 (32.56) | 58 (67.44) | ||
| Smoking | |||||
| Yes | 97 | 48 (49.48) | 49 (50.52) | 36.474 | <.001 |
| No | 99 | 10 (10.10) | 89 (89.90) | ||
| Alcohol drinking | |||||
| Yes | 100 | 50 (50.00) | 50 (50.00) | 40.813 | <.001 |
| NO | 16 | 8 (50.00) | 8 (50.00) | ||
| Differentiation type | |||||
| Poorly differentiated | 41 | 29 (70.73) | 12 (29.27) | 42.115 | <.001 |
| Moderately to well-differentiated | 155 | 29 (18.71) | 126 (81.29) | ||
| Infiltration depth | |||||
| Invasion of outer membrane | 139 | 54 (38.85) | 85 (61.15) | 19.658 | <.001 |
| No invasion of outer membrane | 57 | 4 (7.02) | 53 (92.98) | ||
| Lymphatic metastasis | |||||
| Yes | 96 | 54 (56.25) | 42 (43.75) | 64.179 | <.001 |
| No | 100 | 4 (4.00) | 96 (96.00) | ||
| Clinical stage | |||||
| I/II | 113 | 4 (3.54) | 109 (96.46) | 86.925 | <.001 |
| III/IV | 83 | 54 (65.06) | 29 (34.94) | ||
Cox regression analysis of prognostic factors in patients with lung adenocarcinoma.
| Clinical variables |
|
|
| 95%CI |
| |
|---|---|---|---|---|---|---|
| Univariate cox analysis | ||||||
| Sex (male/female) | 0.576 | 8.562 | 1.779 | 1.210 | 2.617 | .003 |
| Age (≥60/<60) | 0.313 | 3.140 | 1.367 | 0.967 | 1.932 | .076 |
| Smoking (positive/negative) | 1.084 | 33.222 | 2.956 | 2.045 | 4.273 | .001 |
| Alcohol (positive/negative) | 1.219 | 40.277 | 3.384 | 2.322 | 4.931 | .001 |
| Differentiation type (poorly/moderately-well) | 0.541 | 6.526 | 1.717 | 1.134 | 2.600 | .011 |
| Infiltration depth (≥Adventitia/<Adventitia) | 0.625 | 8.288 | 1.867 | 1.221 | 2.857 | .004 |
| Lymph node metastasis (positive/negative) | 1.028 | 31.744 | 2.796 | 1.955 | 3.999 | .001 |
| Clinical stages (III–IV/I–II) | 0.972 | 29.734 | 2.644 | 1.864 | 3.750 | .001 |
| Fn + CD8+KIR2DL1 (positive/negative) | 0.645 | 12.123 | 1.907 | 1.326 | 2.742 | .001 |
| Multivariate cox analysis | ||||||
| Sex (male/female) | 0.577 | 2.332 | 1.781 | 0.849 | 3.737 | .127 |
| Age (≥60/<60) | 0.253 | 1.637 | 1.288 | 0.874 | 1.898 | .201 |
| Smoking (positive/negative) | 0.575 | 1.086 | 1.777 | 0.603 | 5.240 | .297 |
| Alcohol (positive/negative) | 2.319 | 11.795 | 10.170 | 2.707 | 38.211 | .001 |
| Differentiation type (poorly/moderately-well) | 1.930 | 35.893 | 6.888 | 3.664 | 12.950 | .001 |
| Infiltration depth (≥Adventitia/<Adventitia) | 0.649 | 8.227 | 1.914 | 1.228 | 2.982 | .004 |
| Lymph node metastasis (positive/negative) | 0.929 | 22.773 | 2.533 | 1.729 | 3.710 | .001 |
| Clinical stages (III–IV/I–II) | 0.859 | 18.832 | 2.361 | 1.602 | 3.480 | .001 |
| Fn + CD8+KIR2DL1 (positive/negative) | 1.143 | 13.792 | 3.137 | 1.716 | 5.734 | .001 |
Mean and median survival times (months) of ESCC patients positive for Fn-induced expression of the inhibitory receptor KIR2DL1 on the surface of CD8+ T lymphocytes.
| Fn + CD8+ T + KIR2DL1 | Mean | Median |
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Estimated value | Standard error | 95%CI | Estimated value | Standard error | 95%CI | |||||
| Lower part | Upper part | Lower part | Upper part | |||||||
| Positive | 27.810 | 2.801 | 22.321 | 33.300 | 20.000 | 4.284 | 11.604 | 28.396 | 12.791 | <.001 |
| Negative | 40.942 | 1.602 | 37.802 | 44.082 | 43.000 | 3.776 | 35.600 | 50.400 | ||
| Total | 37.056 | 1.464 | 34.187 | 39.925 | 38.000 | 2.692 | 32.723 | 43.277 | ||
Figure 5.(A) Kaplan–Meier survival curve of patients with ESCC 5 years after surgical resection; (B) Kaplan–Meier 5-year survival curve of ESCC patients positive and negative for Fn-induced expression of the inhibitory receptor KIR2DL1 on the surface of CD8+ T lymphocytes.
Figure 6.Schematic diagram.